These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 27005595)
1. Biomarkers for drug development in early psychosis: Current issues and promising directions. Goff DC; Romero K; Paul J; Mercedes Perez-Rodriguez M; Crandall D; Potkin SG Eur Neuropsychopharmacol; 2016 Jun; 26(6):923-37. PubMed ID: 27005595 [TBL] [Abstract][Full Text] [Related]
2. Platform for systems medicine research and diagnostic applications in psychotic disorders-The METSY project. Frank E; Maier D; Pajula J; Suvitaival T; Borgan F; Butz-Ostendorf M; Fischer A; Hietala J; Howes O; Hyötyläinen T; Janssen J; Laurikainen H; Moreno C; Suvisaari J; Van Gils M; Orešič M Eur Psychiatry; 2018 Apr; 50():40-46. PubMed ID: 29361398 [TBL] [Abstract][Full Text] [Related]
3. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. de Bartolomeis A; Sarappa C; Magara S; Iasevoli F Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855 [TBL] [Abstract][Full Text] [Related]
4. Effects of oxytocin and genetic variants on brain and behaviour: Implications for treatment in schizophrenia. Bartholomeusz CF; Ganella EP; Labuschagne I; Bousman C; Pantelis C Schizophr Res; 2015 Nov; 168(3):614-27. PubMed ID: 26123171 [TBL] [Abstract][Full Text] [Related]
5. [Stress and psychotic transition: A literature review]. Chaumette B; Kebir O; Mam Lam Fook C; Bourgin J; Godsil BP; Gaillard R; Jay TM; Krebs MO Encephale; 2016 Aug; 42(4):367-73. PubMed ID: 27161263 [TBL] [Abstract][Full Text] [Related]
6. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Francey SM; Nelson B; Thompson A; Parker AG; Kerr M; Macneil C; Fraser R; Hughes F; Crisp K; Harrigan S; Wood SJ; Berk M; McGorry PD Schizophr Res; 2010 Jun; 119(1-3):1-10. PubMed ID: 20347270 [TBL] [Abstract][Full Text] [Related]
7. What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia. Correll CU; Tusconi M; Carta MG; Dursun SM Biomolecules; 2024 Jul; 14(8):. PubMed ID: 39199294 [TBL] [Abstract][Full Text] [Related]
8. Imaging and Genetic Biomarkers Predicting Transition to Psychosis. Hunter SA; Lawrie SM Curr Top Behav Neurosci; 2018; 40():353-388. PubMed ID: 29626338 [TBL] [Abstract][Full Text] [Related]
9. Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy. de la Fuente-Sandoval C; Reyes-Madrigal F; Mao X; León-Ortiz P; Rodríguez-Mayoral O; Solís-Vivanco R; Favila R; Graff-Guerrero A; Shungu DC Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv105. PubMed ID: 26364273 [TBL] [Abstract][Full Text] [Related]
10. Biological hypotheses, risk factors, and biomarkers of schizophrenia. Fišar Z Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jan; 120():110626. PubMed ID: 36055561 [TBL] [Abstract][Full Text] [Related]
11. Strategies for Advancing Disease Definition Using Biomarkers and Genetics: The Bipolar and Schizophrenia Network for Intermediate Phenotypes. Tamminga CA; Pearlson GD; Stan AD; Gibbons RD; Padmanabhan J; Keshavan M; Clementz BA Biol Psychiatry Cogn Neurosci Neuroimaging; 2017 Jan; 2(1):20-27. PubMed ID: 29560884 [TBL] [Abstract][Full Text] [Related]
12. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Wood SJ; Kennedy D; Phillips LJ; Seal ML; Yücel M; Nelson B; Yung AR; Jackson G; McGorry PD; Velakoulis D; Pantelis C Neuroimage; 2010 Aug; 52(1):62-8. PubMed ID: 20399273 [TBL] [Abstract][Full Text] [Related]
13. Early biomarkers of psychosis. Freedman R; Ross R; Leonard S; Myles-Worsley M; Adams CE; Waldo M; Tregellas J; Martin L; Olincy A; Tanabe J; Kisley MA; Hunter S; Stevens KE Dialogues Clin Neurosci; 2005; 7(1):17-29. PubMed ID: 16060593 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in atypical antipsychotics. Armer R; Miller DJ Curr Opin Investig Drugs; 2000 Dec; 1(4):481-93. PubMed ID: 11249703 [No Abstract] [Full Text] [Related]
15. Possible biomarkers modulating haloperidol efficacy and/or tolerability. Porcelli S; Crisafulli C; Calabrò M; Serretti A; Rujescu D Pharmacogenomics; 2016 Apr; 17(5):507-29. PubMed ID: 27023437 [TBL] [Abstract][Full Text] [Related]
16. Neurodevelopmental Animal Models Reveal the Convergent Role of Neurotransmitter Systems, Inflammation, and Oxidative Stress as Biomarkers of Schizophrenia: Implications for Novel Drug Development. Möller M; Swanepoel T; Harvey BH ACS Chem Neurosci; 2015 Jul; 6(7):987-1016. PubMed ID: 25794269 [TBL] [Abstract][Full Text] [Related]
17. Etiopathogenesis and treatment of psychosis. Crow TJ; Harrington CA Annu Rev Med; 1994; 45():219-34. PubMed ID: 7911014 [TBL] [Abstract][Full Text] [Related]
18. Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia. Preller KH; Scholpp J; Wunder A; Rosenbrock H Biol Psychiatry; 2024 Oct; 96(8):666-673. PubMed ID: 38272287 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Cannabinoids in Psychosis. Leweke FM; Mueller JK; Lange B; Rohleder C Biol Psychiatry; 2016 Apr; 79(7):604-12. PubMed ID: 26852073 [TBL] [Abstract][Full Text] [Related]